SC TO-T/A

0000950123-09-003396.txt : 20090225 0000950123-09-003396.hdr.sgml : 20090225 20090225100538 ACCESSION NUMBER: 0000950123-09-003396 CONFORMED SUBMISSION TYPE: SC TO-T/A PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 20090225 DATE AS OF CHANGE: 20090225 GROUP MEMBERS: BOXFORD SUBSIDIARY CORPORATION FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MEDICINES CO /DE CENTRAL INDEX KEY: 0001113481 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043324394 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A BUSINESS ADDRESS: STREET 1: 8 CAMPUS DRIVE CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-656-1616 FORMER COMPANY: FORMER CONFORMED NAME: MEDICINES CO/ MA DATE OF NAME CHANGE: 20000504 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Targanta Therapeutics Corp. CENTRAL INDEX KEY: 0001398161 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203971077 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-83189 FILM NUMBER: 09632547 BUSINESS ADDRESS: STREET 1: 222 THIRD AVENUE STREET 2: SUITE 2300 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 557-9020 MAIL ADDRESS: STREET 1: 222 THIRD AVENUE STREET 2: SUITE 2300 CITY: CAMBRIDGE STATE: MA ZIP: 02142 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Targanta Therapeutics Corp. CENTRAL INDEX KEY: 0001398161 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203971077 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-83189 FILM NUMBER: 09632548 BUSINESS ADDRESS: STREET 1: 222 THIRD AVENUE STREET 2: SUITE 2300 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 557-9020 MAIL ADDRESS: STREET 1: 222 THIRD AVENUE STREET 2: SUITE 2300 CITY: CAMBRIDGE STATE: MA ZIP: 02142 SC TO-T/A 1 y74833sctovtza.htm AMENDMENT NO. 5 TO SCHEDULE TO SC TO-T/A

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE TO

(Rule 14d-100)

Tender Offer Statement under Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934

(Amendment No. 5)

TARGANTA THERAPEUTICS CORPORATION

(Name of Subject Company (Issuer))

THE MEDICINES COMPANY
BOXFORD SUBSIDIARY CORPORATION

(Names of Filing Persons (Offerors))

Common Stock, par value $0.0001
(Title of Class of Securities)

87612C100
(CUSIP Number of Class of Securities)

Paul M. Antinori
General Counsel & Senior Vice President
The Medicines Company
8 Sylvan Way
Parsippany, New Jersey 07054
(973) 290-6000
(Name, Address and Telephone Number of Person Authorized to Receive
Notices and Communications on Behalf of Filing Persons)

with copies to:

David E. Redlick
Hal J. Leibowitz
Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
(617) 526-6000

CALCULATION OF FILING FEE


Transaction valuation*		Amount of filing fee**
$164,578,333		$6,468


*		Estimated for purposes of calculating the amount of the filing fee only, in accordance with Rule 0-11(d) under the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”). The transaction valuation was calculated by multiplying (a) the sum of (i) the closing cash payment of $2.00 per share plus (ii) the maximum amount payable with respect to the contingent payment rights per share ($4.55) by (b) the number of shares of common stock, par value $0.0001 per share (“Shares”), of Targanta Therapeutics Corporation (“Targanta”) outstanding on a fully diluted basis as of January 9, 2009 as represented by Targanta in the Agreement and Plan of Merger, dated as of January 12, 2009, among The Medicines Company (“MDCO”), Boxford Subsidiary Corporation (the “Offeror”) and Targanta, consisting of (x) 20,991,316 Shares issued and outstanding, (y) 3,390,538 Shares issuable upon exercise of outstanding options and (z) 744,609 Shares issuable upon exercise of outstanding warrants.


**		The amount of the filing fee was calculated in accordance with Rule 0-11(d) of the Exchange Act by multiplying the transaction valuation by 0.0000393.

þ Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.


Amount Previously Paid: $6,468		Filing Party: The Medicines Company and Boxford Subsidiary Corporation
Form or Registration No.: Schedule TO		Date Filed: January 27, 2009

o Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:


þ		third-party tender offer subject to Rule 14d-1.


o		issuer tender offer subject to Rule 13e-4.


o		going-private transaction subject to Rule 13e-3.


þ		amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: þ

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:


	o		Rule 13e-4(i) (Cross-Border Issuer Tender Offer)


	o		Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

This Amendment No. 5 (“Amendment No. 5”) amends and supplements the Tender Offer Statement on Schedule TO originally filed with the U.S. Securities and Exchange Commission (“SEC”) on January 27, 2009, as amended and supplemented by Amendment No. 1 filed with the SEC on February 4, 2009 (“Amendment No. 1”), Amendment No. 2 filed with the SEC on February 11, 2009 (“Amendment No. 2”), Amendment No. 3 filed with the SEC on February 13, 2009 (“Amendment No. 3”), and Amendment No. 4 filed with the SEC on February 20, 2009 (“Amendment No. 4”), by The Medicines Company, a Delaware corporation (“MDCO”), and Boxford Subsidiary Corporation, a Delaware corporation and a wholly owned subsidiary of MDCO (“Offeror”), relating to the offer by Offeror to purchase all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Targanta Therapeutics Corporation, a Delaware corporation (“Targanta”), for consideration of (1) $2.00 per Share, net to the seller in cash (such amount or any greater amount per Share paid at closing pursuant to the Offer, the “Closing Consideration”), plus (2) the contractual right to receive up to an additional $4.55 per Share in contingent cash payments if specified regulatory and commercial milestones are achieved within agreed upon time periods (the rights to such amount or to any greater contingent cash payments per Share that are offered pursuant to the Offer, the “Contingent Payment Rights”), upon the terms and subject to the conditions set forth in the Offer to Purchase dated January 27, 2009 (the “Offer to Purchase”), as amended and supplemented by the Supplement dated February 13, 2009 (the “Supplement”), and in the related Letter of Transmittal, (which, together with any amendments or supplements to the Offer to Purchase and the Letter of Transmittal, collectively constitute the “Offer”). MDCO may be deemed to share with the Offeror voting and investment control over Shares taken up in the Offer. The Closing Consideration and any amounts paid with respect to Contingent Payment Rights will be subject to any required withholding of taxes, and no interest will be paid thereon. The Closing Consideration, together with the Contingent Payment Rights, constitute the “Offer Price”. Offeror expects to pay the Offer Price through MDCO working capital. The Offer is made pursuant to the Agreement and Plan of Merger, dated as of January 12, 2009 (the “Merger Agreement”), among MDCO, Offeror and Targanta. Copies of the Offer to Purchase, the related Letter of Transmittal and the Supplement were filed as Exhibits (a)(1)(A), (a)(1)(B) and (a)(1)(G), respectively, to the Schedule TO.

All references to the Schedule TO mean the Schedule TO, as amended and supplemented by Amendment No. 1, Amendment No. 2, Amendment No. 3 and Amendment No. 4. All capitalized terms used in this Amendment No. 5 without definition have the meanings ascribed to them in the Schedule TO or the Offer to Purchase.

The information in the Offer to Purchase, as amended and supplemented by the Supplement, and the related Letter of Transmittal is incorporated in this Amendment No. 5 by reference to all of the applicable items in the Schedule TO, except that such information is amended and supplemented to the extent specifically provided in this Amendment No. 5.


Item 11.		Additional Information.

Item 11 of the Schedule TO is hereby amended and supplemented by adding the following text thereto:

“The initial offering period of the Offer expired at 12:00 midnight, New York City time, at the end of Tuesday, February 24, 2009. According to American Stock Transfer & Trust Company, the depositary for the Offer, as of such time, a total of approximately 20,577,989 Shares (excluding Shares tendered under guaranteed delivery procedures) had been validly tendered pursuant to the Offer and not properly withdrawn, representing approximately 98% of all outstanding Shares. Pursuant to the terms of the Offer, Offeror has accepted for payment all of such Shares. Payment for such Shares will be made promptly in accordance with the terms of the Offer.

On February 25, 2009, MDCO issued a press release announcing the completion of the initial offering period of the Offer.

Offeror expects to acquire any remaining outstanding Shares by means of a Merger of Offeror with and into Targanta, as a result of which Targanta will become a wholly owned subsidiary of MDCO. Pursuant to the Merger, each remaining outstanding Share (other than (1) any Shares held by Targanta as treasury stock or owned by MDCO, Offeror or any subsidiary of Targanta, MDCO or Offeror and (2) any Shares held by a holder who has not voted in favor of or consented to the Merger and who has properly demanded and perfected his, her or its right to be paid the fair value of such Shares in accordance with the provisions of Section 262 of the General Corporation Law of the State of Delaware) will be automatically cancelled and converted into the right to receive the Offer Price. MDCO expects to complete the Merger as soon as practicable pursuant to the short-form merger procedure available under the General Corporation Law of the State of Delaware.

The full text of the press release issued by MDCO is attached hereto as Exhibit (a)(5)(L) and is incorporated herein by reference.”


Item 12.		Exhibits.

Item 12 of the Schedule TO is hereby amended and supplemented by adding the following text thereto:

“(a)(5)(L)

Press Release issued by MDCO, dated February 25, 2009, announcing the completion of the Offer.”

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Dated: February 25, 2009
	THE MEDICINES COMPANY
	By:	/s/ Paul M. Antinori
		Name:	Paul M. Antinori
		Title:	Senior Vice President and General Counsel


	BOXFORD SUBSIDIARY CORPORATION
	By:	/s/ Paul M. Antinori
		Name:	Paul M. Antinori
		Title:	Secretary

EXHIBIT INDEX


Exhibit
No.
*(a)(1)(A)		Offer to Purchase, dated January 27, 2009.
*(a)(1)(B)		Form of Letter of Transmittal.
*(a)(1)(C)		Form of Notice of Guaranteed Delivery.
*(a)(1)(D)		Form of Letter from Georgeson Inc. to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
*(a)(1)(E)		Form of Letter from Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees to Clients.
*(a)(1)(F)		Form of Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9.
*(a)(1)(G)		Supplement, dated February 13, 2009, to Offer to Purchase, dated January 27, 2009.
*(a)(5)(A)		Press Release issued by MDCO, dated January 12, 2009, announcing the execution of the Agreement and Plan of Merger among MDCO, Offeror and Targanta (incorporated in this Schedule TO by reference to the Schedule TO-C filed by MDCO on January 13, 2009).
*(a)(5)(B)		Fact Sheet issued by MDCO dated January 12, 2009, regarding announcement of the Agreement and Plan of Merger among MDCO, Offeror and Targanta (incorporated in this Schedule TO by reference to the Schedule TO-C filed by MDCO on January 13, 2009).
*(a)(5)(C)		Transcript of the conference call on January 13, 2009 regarding announcement of the Agreement and Plan of Merger among MDCO, Offeror and Targanta (incorporated in this Schedule TO by reference to the Schedule TO-C filed by MDCO on January 14, 2009).
*(a)(5)(D)		Notice dated January 26, 2009 from Targanta to Holders of Stock Options under the Targanta 2005 Stock Option Plan (incorporated in this Schedule TO by reference to the Schedule TO-C filed by MDCO on January 27, 2009).
*(a)(5)(E)		Form of Summary Advertisement published in the New York Times on January 27, 2009.
*(a)(5)(F)		Press Release issued by MDCO, dated January 27, 2009, announcing the commencement of the Offer.
*(a)(5)(G)		Complaint filed on January 21, 2009 in the Superior Court for Suffolk County, Massachusetts.
*(a)(5)(H)		Amended Complaint filed on February 2, 2009 in the Superior Court for Suffolk County, Massachusetts.
*(a)(5)(I)		Notice dated February 11, 2009 from Targanta to Holders of Targanta Warrants.
*(a)(5)(J)		Notice of Motion and Motion for Preliminary Injunction and Memorandum in Support of Motion for Preliminary Injunction filed on February 17, 2009, in the Superior Court for Suffolk County, Massachusetts; Affidavits of Juan E. Monteverde and Matthew Morris, filed on February 17, 2009, in the Superior Court for Suffolk County, Massachusetts.
*(a)(5)(K)		Press Release issued by Targanta dated February 20, 2009, announcing the settlement of the shareholder litigation relating to the Offer.
(a)(5)(L)		Press Release issued by MDCO, dated February 25, 2009, announcing the completion of the Offer.

EXHIBIT INDEX


Exhibit
No.
*(d)(1)		Agreement and Plan of Merger, dated as of January 12, 2009, among MDCO, Offeror and Targanta (incorporated in this Schedule TO by reference to the Current Report on Form 8-K filed by MDCO on January 14, 2009).
*(d)(2)		Confidentiality Agreement, dated as of October 6, 2008, between MDCO and Targanta.
*(d)(3)		Form of Contingent Payment Rights Agreement, to be entered into between The Medicines Company and American Stock Transfer & Trust Company (incorporated in this Schedule TO by reference to the Current Report on Form 8-K filed by MDCO on January 14, 2009).
*(d)(4)		Form of Stockholders’ Agreement, dated as of January 12, 2009, entered into between MDCO and each of Caduceus Private Investments III LP, OrbiMed Associates III, LP, Radius Venture Partners II, LP, Radius Venture Partners III QP, LP, Radius Venture Partners III, LP, Radius Venture Partners III (OH), LP, Seaflower Health Ventures III, L.P., Seaflower Health Ventures III Companion Fund, L.P., J&L Sherblom Family LLC, Skyline Venture Partners Qualified Purchaser Fund IV, L.P., Skyline Venture Partners Qualified Purchaser Fund III, L.P., Skyline Venture Partners III, L.P., VenGrowth Advanced Life Sciences Fund Inc. and VenGrowth III Investment Fund Inc. (incorporated in this Schedule TO by reference to the Current Report on Form 8-K filed by MDCO on January 14, 2009).
*(d)(5)		Memorandum of Understanding, dated February 19, 2009, by and among (i) Levi & Korsinsky, L.L.P., Lead Counsel for Plaintiffs Martin Albright and Vito Caruso and the Class, (ii) Ropes & Gray LLP, Counsel for Defendants Targanta Therapeutics Corporation, Mark Leuchtenberger, Stéphane Bancel, Garen Bohlin, Jeffrey Courtney, Rosemary Crane, William Crouse, Eric Gordon, Ph.D. and Dilip Mehta, M.D., Ph.D. and (iii) Wilmer Cutler Pickering Hale and Dorr LLP, Counsel for Defendants The Medicines Company and Boxford Subsidiary Corporation.


*		Previously filed.

EX-99.A.5.L 2 y74833exv99waw5wl.htm EX-99.A.5.L: PRESS RELEASE EX-99.A.5.L

Exhibit (a)(5)(L)


Contact:
Emily Poe		Robyn Brown
WeissComm Partners		The Medicines Company
Phone: (212) 301-7183		Phone: (973) 290-6000
epoe@wcpglobal.com		investor.relations@themedco.com

THE MEDICINES COMPANY ANNOUNCES COMPLETION OF TENDER OFFER
FOR SHARES OF TARGANTA THERAPEUTICS

PARSIPPANY, NJ, February 25, 2009 — The Medicines Company (NASDAQ: MDCO) announced today the completion of the tender offer made through Boxford Subsidiary Corporation (Boxford), The Medicines Company’s direct wholly owned subsidiary, for all of the outstanding shares of Targanta Therapeutics Corporation (Targanta) common stock. The offering period expired at midnight, New York City time, at the end of Tuesday, February 24, 2009.

According to the depositary for the offer, as of the expiration of the offering period, a total of approximately 20,577,989 shares of Targanta common stock (excluding shares tendered under guaranteed delivery procedures) had been validly tendered pursuant to the tender offer and not properly withdrawn, representing approximately 98% of the outstanding shares of Targanta. All shares that were validly tendered and not properly withdrawn have been accepted for purchase. Stockholders who validly tendered and did not properly withdraw their shares will promptly receive the tender offer consideration consisting of (1) $2.00 per share, net to the seller in cash, plus (2) the contractual right to receive up to an additional $4.55 per share in contingent cash payments if specified regulatory and commercial milestones are achieved within agreed upon time periods, pursuant to a previously announced Agreement and Plan of Merger among The Medicines Company, Boxford and Targanta, dated as of January 12, 2009. The consideration paid or payable for shares tendered in the tender offer is subject to any applicable tax withholding, and no interest will be paid thereon.

Boxford expects to acquire as soon as practicable all of the remaining outstanding shares of Targanta common stock by means of a short-form merger under Delaware law. In the merger, Boxford will merge with and into Targanta, and Targanta will become a direct wholly owned subsidiary of The Medicines Company. Pursuant to the merger, each remaining outstanding share of Targanta common stock (other than (1) any shares held by Targanta as treasury stock or owned by The Medicines Company, Boxford or any subsidiary of Targanta, The Medicines Company or Boxford and (2) any shares held by a holder who has not voted in favor of or consented to the merger and who has properly demanded and perfected his, her or its right to be paid the fair value of such shares in accordance with Delaware law) will be automatically

The Medicines Company 8 Sylvan Way Parsippany, New Jersey 07054 Tel: (973)290-6000 Fax: (973)656-9898

cancelled and converted into the right to receive the same consideration per share paid in the tender offer.

About Targanta Therapeutics

Targanta Therapeutics Corporation (NASDAQ: TARG) is a biopharmaceutical company focused on developing and commercializing innovative antibiotics to treat serious infections in the hospital and other institutional settings. Targanta’s pipeline includes an intravenous version of oritavancin, a semi-synthetic lipoglycopeptide antibiotic currently awaiting EU regulatory approval, and a program to develop an oral version of oritavancin for the possible treatment of Clostidium difficile-related infection. Targanta has operations in Cambridge, MA, Indianapolis, IN, and Montreal, Quebec, Canada. For more information on Targanta, visit www.targanta.com.

About The Medicines Company

The Medicines Company (NASDAQ: MDCO) is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex® (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has an investigational antiplatelet agent, cangrelor, in late-stage development and a serine protease inhibitor, CU-2010, in early-stage development. The Medicines Company’s website is www.themedicinescompany.com.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the proposed transaction between The Medicines Company and Targanta, the expected timetable for completing the transaction and any other statements about managements’ future expectations, beliefs, goals, plans or prospects constitute forward-looking statements. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause The Medicines Company’s actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include uncertainties as to the timing of the merger; the possibility that various closing conditions for the transaction may not be satisfied or waived; the effects of disruption from the transaction making it more difficult to maintain relationships with employees, licensees, other business partners or governmental entities; transaction costs; whether results obtained in clinical studies or in preclinical studies will be indicative of results obtained in future clinical trials; whether, if The Medicines Company consummates the acquisition, The Medicines Company can advance oritavancin

The Medicines Company 8 Sylvan Way Parsippany, New Jersey 07054 Tel: (973)290-6000 Fax: (973)656-9898

through the contemplated Phase 3 trial on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies for the product; whether, if oritavancin receives approval, The Medicines Company will be able to successfully distribute and market the product and in that regard, whether physicians, patients and other key decision-makers will accept clinical trial results; whether The Medicines Company will be able to obtain regulatory approvals and such other factors as are set forth in the risk factors detailed from time to time in The Medicines Company’s periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in The Medicines Company’s Quarterly Report on Form 10-Q filed on November 10, 2008, which are incorporated herein by reference. The forward-looking statements are made only as of the date of publication. Except as otherwise required by law, The Medicines Company specifically disclaims any obligation to update any of these forward-looking statements.

The Medicines Company 8 Sylvan Way Parsippany, New Jersey 07054 Tel: (973)290-6000 Fax: (973)656-9898

GRAPHIC 3 y74833y7483301.gif GRAPHIC begin 644 y74833y7483301.gif M1TE&.#EAN`)B`.8``-_=U9B3J%919VQF=@D&&=O3BW$I'7'ATA=O@ MT]7?XJ>HMBU`FL;%RS,O1MW;X]OBRKNVP^#=V-[>T;>TN\G(T^#:XN'=U(%\ MCN#;T2LF.XJ&E1(5-MOAVJBCKN'>U72&NMW=V\*]RY^;J]OAY&!;;=W;U8B% MC+&LN:ZQNN'FZ.#:WA@4*.'=SVI:5GN# MVMW9VD`]4-K4V][#=WI&+G=+:W=G4U-3;T-G=U0<%'M_B MU,#"R-O7XR`<,9B>J=S:TMG:W]G9U=G?T=K>WM;BV=G9VMG8T-_=Y^#5WU=_>CJ\!$.)LW4S=?CU.39V^38X,?(P;^\ON+XN#?VJ:PLGR$BN'6UN7:U^/;T0X+'.+?T^+?V.'< MV.3;SOGX]RQ&G>+=VJ&@H(^/H-?;YA<1-0X**[2\O>#>UPD'&R'Y!``````` M+`````"X`F(```?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@ MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S- MSL_0T=+3U-76U]C9VMOKK[.WN[_#Q\O/T]?;W^/GZ M^_S]_O\``PH<2+"@P8,($RI9U\-JK><-F$ASW4U*QA1MW9;NW\.'(+26_ M,HR):-R\HT![`APX+&=W91/?'5N*\]94FJ$VA>TT\^M07@=1IJ17J>5.B1]? MIJHX67#AHAB?MK1[*5_,I`CH;3W]CUW'26^G))YX^6+0VC'U%1L<*F#?:C7Y MS6W,+63IK&5;+[\Z?>7L;NT6[SH_-G;$R''"G6K;$97$`P@^L$$2_?E7"0$' M)KA!"W#8)YY4"6:X084"0B;(!@@(\`"#@`GH5E!)Y"!B$A4ZN`M1&TC(HG>= M$=!"A@DR6)]02;10U(D0XHB@CC_"L0$7+E[BF?]0((KH8X#JV2@D@ON5)-T` M*6200`9`?,!!$DE20D`&#FR9P0P,Y`&F=%`R%U09,.21P)Q;#K!F59"UD$$* M0&201PHFT#A)=F5@20(*0*20`(>$<<'GG!Q\D`("+599"7X(')&!EG-F@`!P MI!%`PJ>XL2E6!A)LJFH&.8065`XP#!#FI9`E,4,%*&00``,Y6'JI4#F0L>JF M`Z#TW!\#)#"(D1\$T`)Z`G*0PB!0`1R&"0O)44`E(\$"% M1C[@82;Y$2"`!3F408"1WLZ*"Q`:%P!G?@@N<4"J06FIV M*.1!7U?[9D#&$96N^Q?_'!Q8<.Z\5/HJIL`KE)$7'QYW1%1VR";`9E`"K*!O MJ'=Q4$%@"-C`!7DE0T):&2OD\!N[TL$QQ0"APA>?DM+]\<$,)/.5LRX$\&'! M!G#!40$)7)!6%7P"I,"AA6Z&FC!:XS8_=A<+,1M7AHZE@O=ES7V>+*UT+6R!@M-NK%5%& MF6-%G@L!7#BPP7L$L&'!LW;_JI0`*A2LF[V,`$G`V#]ZUO##YA%@`@EPF/!! MQ;#'+MT#8CR;W7G!+W)5WF7,Q[=)?L\+^'L/I(%`T3%7X#R$6\C+^&)$\=RK M_W!/1T(5'%LL:I2VS"F5P@R5PE5,$5*WG;32#'C/"?)=?RM5^8^0'>U*9;L9 MA&-@`;F$!>#=K?4Q`0A02LZ7G#H)_&(`.''%C` M>V1HD>C!80`S0(`69K?^!9`G(@1SFJ*W4? M`TP9RO6!`6S(@HW06N\DH*B-(;(7H!L!!^A$@A%HX?]K.F39$0J)`$+>"6AB MF^)]"(""!1;2E*,(G;(`LP$8^`R*BEA9$CC@`!*8X)&7G`0&5T#*4E*-@R@; M@`H&D*P!(`!,?&-C%#E0!0&88`!X.$*O/(1+0^SL`"A@Y@"N*8`692X[24`` M$$80@`<"LD0I0H$#/O"`;L(B:B-(@`E,D(`7*`$.=-D:8`10!7&*LVV90Y@J M+P,8%!Q!G%I@YNA"400!5(!J28'###C`*!,-)0D"P$.96A!,26!P"P9EIN60 M"9@W)F`Z=:E+]GB4`@8T16N-(`$MH-6;CKOE@.22K2(8$:$(](U2-J#- MOZX"GR)L"@)&0%+?>%0`:VB1WZ2I"/0DS*J74@K#N-K5C^WM#P^H@@D$P%IK MLDYE.)5+4`:P!2+E](QZJPWT&C0GH[T--WH-U0:0L*;[@2^0CP-MC=95!FVB MY2U6"Y16^,#4$BF%!"DP'F<1(136:=:QA?#L]0C4.(8YC+S+?4P+2*"RO;VJ M`L5-#F!R<(%ZAA*W(KOB=B42/0(D:RH;S.O,BI8`WGU//($MVES%]%T(51`F2G"5E[I,F. M%G3P,D!R*P.M;>TI%],4(%S+FA4PEYLO@9X!7&NU'QB!Y9K\"GP=\ST8X\#- M3%11U69ZK&[E=%!4P(%;"Z!59BS"X7RM+XM]K"D;J``,8_]J($"!US=<\#2F M!\"`#VS:T+A=[:V-91VJR/$][%//-?&3'2YP8+R`-'<>ULUN#KB3TV*!@SH9 MD"7[L9H0Z"EBHDC`@8W=FQ7T2T`'2C24!V3`1QY]P`S8S>X!Y%H\D!D`PP.0 MAP`4RXQ,9#B[!0`SKPKB`0['7ET&H`7@Y$D`>9!4!NQ]WP=HG.)YX/94QN6> MVG6;.TAV3M)2\V]P\=2C-#^9,:TW_2GCGKI+27.06/Y[%@K@.C[%P'N\[%KMM]H-WLF/3ZY^0^#+HK MK^UDHW$N\9Z/LA'3_K2F_[TJ$^]ZE?/^M:[_O6PC[WL9T_[VMO^ M]K@W2@=VS_O>^_[WP`^^\(=/_.(;__C(3[[RE\_\YCO_^="/OO2G3_WJ6__Z MV,^^]K?/_>Y?OP'@#[_XQT_^\IO__.A/O_K7S_[VN__]\(^__.=/__K;__[X MS[_^]\___OO__P`8@`+(?W90@`9X@`B8@`JX@`S8@`[X@!`8@1(X@118@19X M@1B8@1JX@1S8@1[X@2`8@B(X@B18@B9X@B$X@"JX@BS8@B[X@C`8@S(X@S18 M@S9X@P(8_P(ZN(,\V(,^^(-`&(1".(1$6(1&>(1(F(1*N(1,V(1.^(10&(52 M.(546(56>(58F(5:N(5<:(4+\(5@&(9B.(9D6(9F>(9HF(9JR`1LV(9,``%P MZ(9J.(=T6(=V>(=XF(=ZN(=\V(=^^(>`&(B".(B$6(B&>(B(F(A@"`*,V(B. M^(B0&(F2.(F46(F6:(D8\`::2`><2`=N\(EN\`6B>`>D6(IW<(FHF(JJN(JL MV(JN^(JP&(NR.(NT6(NV>(NXF(NZN(N\V(NZJ`'`&(S".(S$6(S&>(S(F(S* MN(PG<`(`<`(44``4``#/B`/6B`,\D(W:R`/+V(W>^(W@&([B./^.Y%B.YGB. MZ)B.ZKB.[-B.[OB.\!B/\OB.(E"/]GB/^)B/^KB/_-B/_OB/`'D#`CF0-^`$ M"G"0!^D!-K"0-O`#/V`#`!F1$CF1%%F1%GF1&)F1&KF1'-F1'OF1(!F2(CF2 M)%F2)CF2,I"2*KF2+-F2+OF2,!F3,CF3,WD%%&``&'`'+'`!%Y`&:7`"<9`% M65``.&`#:?"0$$F32KF43-F43OF44!F54CF55%F55GF56)F56KF57-F57OF5 M7#D&8CF69%F69GF6:)F6:KF6;,F6!I`%%#`!,3`%(_`!V'4&8@"-5Y"-DD M`#,@!34@!F=0`4)0`YYI`"Y0G,9I`'.0G,I)`YXY!LE)`V9@!59P!9Y)`V/P MEEE@`&.PC=KH!VA``3=9G`9``^19GAI@`.@)G@I0FAB`EL.)GO`9G_&)!M\9 MGB[0B6\P!N0IEAA``W-0`\+9F30`H,G9GF/0G,JYG*7IG*D)`%:@`-3)G@*: MH,_YGO*)DQ*:H1JZH1S:H1[ZH2`:HB(ZHB1:HB8*HGZ0HBJZHBS:HB[ZHC`: MHS(ZHRPZ`5B`_P4B8`9+```40`0KQR$M`"+),FA`$`8]D`,/@``<0`$M.@'< MF8T3$*52.@%-&J5F<*5H8`552@%".8W_":!@:@-/`)$38)W0>:5H"J8X*@,W M(`-1Z@?42(TM"J9T&J=V:I/@F:=Z"IY7\`1/4(_[R8GY"0!7"IX`8*,L\`-- MFJA8,`$\>@55.J5O.J-2BJ9H8`8TZJ*2*J4MBJ=Z"JF9&JJB.JJD6JJF>JJH MFJJJNJJLVJJN^JJP&JNQ>@5H<`74.`$G<`#6YAL;D`!]T`-!$`0EH`=3(`0. MD`-[$%%&L*@LT*S-B@5V&J1JN]$H#%\"MS5H#7T"6(#`!9L"GASJI M-1JEZSJ-+$JO`$"CU.J?IHJPTTJOLAJQ$CNQ%%NQ%GNQ&)NQ&@NK5Z``%*`! M4I`&3)`!8%(&%D4&LID#,_('>V`"^2)''%``+6H%3N`%3F"0!_FI['JP`&"3 M&*`!8S"H";NBSTB-.WJM[&JK6$">!7J@P2B6_CD'/,"T._D#CAJ-MBJG*7VNH-'"H`*`&SPBG9NL'$W`'95JAU.B,*LJNACJT/$N-5W`%(#"- M9ZNB<2"O3)JBA[H#70NG*=JQX+F=/%`#A*O_HM$*N'+0C"IJD_(ZM'&Z`VH` MI[>JM1N[N9S;N9[[N:`;NJ([HU<0MDV`!`(P<,F&!$``3";05V^!`'V`)DP@ M!],J!7$`GW&@`3^`!6J`!4U@N2K:C`=P`DNP`\%K!FB@!I=+M(^+`[Z;L&9P M`LQ[`CO`I4-)`0I@!%9`O`=@!69PLTZ0IP7`J7X@!TM`O73KM=$8C=*X!!1P M`.E[!7*@!A.P`\=+O6JP!&I+`R?@!P40P$8PP`H@`TT@`@@-0@`8`P+\J*@<`@`4XP`(XT(P_@`,Q8`-[[+X*0`10``4>X*=/4`(" M"05>X`5$D*4GD+5^8+DT',$.RKU6L`3+>[\G<*,WN@.]2\<.";T5[+M&4``( MR<9/<`-_ZJ@88*X/[+LNN@-8D`9U?*[WZP_/_- MX*RB-$`%+/`$?:`O>X`"J@50<)$B",5B,*``$1`!+=H$#+`&][P&^)P"(W`! M,"`!/:FB(%`!/L`"8&`!^:S/0K"W?G`%4B`&DO+`(O"&,%!3%@`!3W`$#+#1 M&[T&?1`$7^@`^HS/##`"2("]?H`#%9`"9^`#FJL#$O`!,CT"W.K/DE(!LHP% MOGD&0N"0+(`%9_";10D!*D#2'=T'(N",-$!)D@(#B=JD>AP#=2DI/D"](8P% M%2W3#L"3*EH%8K`#F"K"`'`&O(D#(JW/?>`#N&J[?E`%%2`%B[L$85`%QYNB M/W`!$F#22)`"/E">8RL&P!G482#+0!S.AGW8B)W_V(J-J@`@!41P!`*`80)0 M)A&6%!F`!!+P0_)6!0'@`CZ2`Q!@!C8$!USF`S+@!&;`(AL0!D3` M!*,C%22#`$R`!CW@0V+!!;TZ!9VJ``[@2"T@VR!W`!$P!$P093V2!!N0`3!@ M!1%0`!^P`7EP`W'PQCI`:`Y`!%'``;(]VIDB`G`I!`FP`2/P`\TZ!R-`'N1"CMA6$`0< M,'`Q=@1^)'0<@`-J8&U"`0<9(`7TW*(Z\`4XX"D00`53\`-0<-I#,(TWZ6)* M0`%,D`!:L`!70,<`<`#->]L>,%X;,`-+T`:$%A1:0,.R(F9PT.?T(P`WD$<`!0<4@EI,T*(G4`4YD`,?@`-M,`(9,`!4'@51E@`C M4`(OT$X(T`,18`0?4`8M<`0K;@8S<"15H``BL'(0(`*0;0(B4``G8$LM``1U M#/^@/W!#*.`##7D'.(``)@`%1G`$#Q``4I`%.I`#)O`"6A`C`_`$'A#60Y[O M^K[O_(ZQ#NH#!`2G`"-H#F4-#@">O2C/L$XV4C?`(FUJ$%=W#B1$$">K`` M>L`$5I`%(D`T21``$``#L6TC="T$`B`=2N`";G#G7.`[/G`&L]D%A#L`^`%L+Y/9(`#X`D" M=_`#%&`$*9`$'V`$4Q`%:'`"$D#%4;`$9Z!GL(($8F#_<'M@`?2Y<@SN!#(F M`U?P`Z?-`3F@`SQ:`TA@`EK0`@D``S%P`!2``%J`[E'``"V``C`@1Q[0![[(_^[1?^YD*G2\P7@A``^,5:9H#V`+`!`!_,@]@`7^[HE=P`G*0 M!9[B`75/`4YPVD&@`Q!@`Q=`!AL0`$MPYFD^QTV@!CM`MP!0`BN?0#?S%GE^ M!7NN!5P4*4U@!(*NW21@!FJPZ8#!`2Q`]$1Q]&``"`)%10DQ340'(CI.=RIE M13E/+!`"!(,$27E3900;#@I8&Y@)'*42)U4Y?T5[)BEZ0Q%^LP!^`&(;*1!$ M62`@<2=7,0@"47(8!@485`$;_SU6'R9Z`@@?.1QZ+9\R&1M31%$9"#$B8@@S M1#DD"A%S4R8<9SE`2%E."%I0$5=$0`\Y.6`,\?(B#Q`'5I9,F,6PH<.'$"-* MG$BQHL6+&#-JW,BQH\>/($.*'$FRI$F&`-0\&<`'$@T$EHH06%6$RP`$.:94 M^-!BD*<3#Z_0&)-%G(1>!L,.%`%BU;9QXX MD%&`PO\$+"`F"$N2P<,%`UGBU,!08<_L:$AP/4!0)=NV#+PS#'@`1$>:#`^. MW,@@@$@$-4C@,9GQX,,)(_CTT5!`)L$&!E&<&+F!!`D:"@`6GMS/O[___P`& M*."`!!8X$0!F+,!!2P]/!$"Q8H8$,&+:28P`!%`#D.@X0&\)6R@A!=1 M))!/!%E,`,`2!S!$`1I><:$"&3FPQ@8<10AIA5I_``'#"UT,X40$,0Q0Q%PN MN"!$)00`0_!I$!`8`AP$&R"I+[>:<=^[YYZ"'/@L%5L#`@%@DA`':(#(-4H8* M%H!&0`LTGMN0;A$HT"X`7WNA1`XRQ"&"&1$$H6\$'B0P@#Y9W*&&&@W)T43" M*MA0A1`R/%S$`#>803$)>NC1`Q$%<.QQ$B00$48"+?Q1AAA&2*'S'P%0P`,* M$+>00`I'J)!!#E4`@Y@@<0,00,`$.PL`#HXP&)\X0`1ORM`"HA"%)J#!!RD* MPP)@\("=5?\`)56K4I)*@(8"9`$'33""##Z0BR7,`09'=&A,HQK7R,8V-@12.(#`8!`@`2"8X`$0:QT< M!O`$$K!I)B;P@0Q^$!1V>`$%"(``!0P0`2C,ZS`)$1B"7TB@ M!@U@L">5X0+$]C""+S@"$D0XP040R+,3Y'(PG7C@%$0!!UJ6`0'_4>A!);BP MASWPH1,]>,@.1I`#!*2`#$BP``D&X`-PQ`@%#H``#$A03AB`H`#1N,`2P#`' M"G@15')@03=8,`$-T(`)#MA`%W80AQ->``$#.($.M(""^XP!##I``!\$@$L# M7.&+/8A`!-#@QI*:]*0H36E_;D.#$XA@!F%!@`6>0`0\".`!#Q``":PG")EL M0`SRN1%*>L#B`'E/Q` M`&5(0@5^\`4W7($#+>!"`@Z`@P24H2UPA2+:GM:6,K1@`P*0``0\X(0"@+4% M)#A``330`Q*LJ0A_N&L"A'"`,R2!"PA0_X`<9!G6`.P@;Q)(0AD>4`4C[.`! M;VT+6Q()@10@`#4MR($$;O"0"5!A!";8`$`V\(`$H%`-.D#!`S8@N-I:X`)& MH,`9!G`!`/"3`D90P$]^H-L+"$P*/DB`"4JP`PT8H0D78.H1TC``#AQ@"1KX M`@XL(",T1(`&5I`!`Q`04@580:7PC:]\YQO?=&'A8!S\@TT<,`0/6$`,8G!` M#'`P`]3`@0--&*-^&@*`*RC5`1+``08`T,@7,``+!L#"!+)@!0;T0`%4D$`` M6C4#/(3A!&9@"`WZ%H``P``'-:C!%8[0XE.<0,1Y"``0=$R"=MI`Q"T.``E@ M=X-[#8$(9YA!`/\L<`!DH:$'%8H0>DLD093)!@`%RNM?U4P!.F\`,-\`X-<"8U`'@'``B( MH&L[L($'H/`$$8R[%K2@00P@``$;8*$&<[C"#9X`@1\,A09FT)H"B$#_!'8H M`-STKO>@(N`$!3C\X3:P`=?LX00BW"`Q7YLP!"$W&1275"PV5.*(>XF@88N(+6T'`!8D_@4"4'`QB^P`,ZT`$+ MCRHY%@"`[YL;*S]W>'HMS"""X0F,`LKZ`0Y^\'&!C3O?"JCZ&%=LAA\0&S\+ M#K;:U\[VMGO$OHRQ^!/S!!ER,`$);LU3"SC@@P*[78P[H7,0<8'-T/@QV"`,2I`Y@7/G0)D(`*6/_STIT?, M%1XU+&L][]XUT'"K#55Y,P!@!RM&2U86`H`Q_W#>\Q$8H_`]?W`TB"#B05F] M\EL]A^8WO^E#>8/1WZ!X+]'`^=CG/;QG,0';>XGU^3'6LABB?`!HN,%>R@\- M*N_V]KO__?"O_`0.L&X/..`!,RG"D1[SAR0\P`0D8`8%4`!8,'2"AR[XYG`4 MH`%S8'UC,&&+AQ]9X`)64`)/8`76-F%>DG9J``*5\W5@!R]O\`:^-V$11V\V M(`)U8WPB8`4NJ`8_8'JG=P4&X`<_1X,"1P%W('0V<'(8<'WGMTAQ``)^H"YS M,&$T`'N'8@5F(`-?\`6Q9P8.YX(O^`.$]!!U(P(L('1@X`(&,`:7%WM0H"O! MUWSO=H;7=P=W,`>^]_]NK882&#`&1,AZ^*$&.'`'!D"$?N""$U`#4.4EM@`` M(#!N23@'\'>(B)B(]#4!)X"!N/4!'103&&("(T!3'7@%MS$'VS* MNV@+Y0<`RY=V#<&'$S",1SB( M&S@!5&@%NJAXJWB,XQ:(;X@2\+9\M;!BO@"*F-B-#=&.SJB(]%B/]NA&<;`$ M/_`"+T`5.<``9/`""98%]UB0!GF0")F0*K5X>G,#*H`'$A`$'D`$%%``+J#/ MD!B9D1JYD1P)($GX)R?@`7S5A"=``TO``SS0D2JYDBS9DBXY;#U'#F9@!I$4 M23W'`BZ9DSJYDSP)?S!Y`5QG+#59DU?8DT9YE$B9E&S4:J'H"Q-V!:BGE%(Y ME50);`=PE5B9E5JYE5S9E5[YE6`9EF(YEF19EF9YEFB9EFJYEFS9EF[YEG`9 MEW(YEW19EW9YEWB9EW-9!WS9EW[YEX`9F((YF(19F(9YF(B9F(JYF(S9F([Y =F)`9F9(YF919F99YF9B9F9JYF9S9F9Z)F8$``#L_ ` end GRAPHIC 4 y74833y7483302.gif GRAPHIC begin 644 y74833y7483302.gif M1TE&.#EA<0$M`.8``//S\_S]_+JWPFIC>NOK[-WWL\$1"6V%==E=1 M;?O]^/WZ^Z>BKL_,U6IE@_K\]OW[_/K\_-_=Y/W\^GQXCOW^^!<3.]31U/CY M]?[^]P@'+E)-9]S:WOW^_O3T]O+S[:2@LO[]_81]B9N8L-?5W(R&GZRGON?F MZR,>2#,N4_W\_3W^[P[._N\?7W^5]5?V5;@>OIZ2'@YOO]\]71SU5, M=75PC,[+RZ"?L/;V]?GZ\_CW^JBBN!02,NCIZB`>0`T*,?[^_?[^_/[__O[_ M^____O_^_O___/_^^Y.2J=G8X=+9T]#0VUE5A!`.+?[^_O___R'Y!``````` M+`````!Q`2T```?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@ MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PHQ^0'7&0,;'!W5& M&0)YT4X!/'YU4]()P@X=<9343C)U M1$==$O8Q5\=6Q4#X6(.NR8'2!`$.4LQ#UN!H7_]^&U;8&AP!I,,>>-%-1]U# M<`S8UWARX#B!#'`\`)85/EWP!0T$,&%!'QE5\($".^2Q04\B8)#`'@,@$,4" M3?1@FA]))"$##$#\]U]]+[13GR%R>!-`$@$$`!Z83.&`@P3C)9',8S+052A" M%8*G'WB1ML<`9P$96I\?$O(`AZ&//91$?%+*(=]T$!8I"!WG271J'(+Y(=^# M\U%C83H>CZR5^!AXV*$*:Y:$L'H>!YSE9^$B$#&`0WI"MG-D>:V=9^!C MU1WICB':6%-'$A`F,2.2G^I*G@SS<6A?>?I)>5X<,J23C+QS%5)3I%:.J@X= M#-LK2'W50.H`!$=44$/_&4;`$,,";FRDT10AF'$&%!Y'(``0$B@`0A!1./'2 M('"DP(`+IS*0PLTW,R"#1"DL2DAW+DB`$!#.O0"$#.<=X)R-M[(#1XE;!2!= M,4:[<\`+)7:%L\S316KSUO@2O14)6R!R`-A`N)G3, M"P#+(`-Y@^&0:#OZ79WUUBE(8"^KD<(@\WET5+C(CG"@5^`<#)3TPL+M3)`` M#)%*'1U3<\&A]B`&2MH:L,XEH4*BR=Q1QSB#\.KI.N2Q.C40/&"7I3JMH4HV M(7)()#4#0N*(NXH-PEXMH'XLH4445V@D`@428(!"%1YO-,41;'I,6P\XP"'# M_Q+JO.RBW"JL7J([@=)`^0W5/1EI'"I8X]ZE.SHWNHOX2B>#^_E#DCJ2D)[O M)&-]0+##M>![PYN`") M"5D5H`0HOBC9JD)ST,`<-%6(.-``#H$Z#P^2`(-XA6<.#H,20@H2`@NPH0(# M((`+"#"G[&FD"F1HP0R4T*:Q>*$'`$D'%97WAP"D0?]G@)J5H?P`@T8Q`$>% M"(`,7H"V8N@M``E(0``X%P`.:*".K@&"&E0`@UB"B37@2<+E7!!+A(G!!3#@ MG`9@-0%Q!4J4_PE`"F#0S!T%J$)`2,`T`^`<3LI!`RGH@1'"$`8G<"Y+=.@4 M+!.P!""D0T`I<$$*9"FUW#TJF[%,@!\D(`5D]G*9H]051`+`EK9H"G=T`*0B M8I:`+83!+3R``;D`,J,7%+0'2S#?'P+2SJ7\;A#$'%CO9AE+FDGJ1(-(PA>2 MH1_V($R8Q=#6P%[P`AA,)%`Y$E",`G6#!&0!`0,80!`4\(``$&9_.GT4%1RP M@(J]X0QHR,,"*IF]"`SA"P3_"$'T/#:%&:`A.UFTUP1"$-0!M.`$%BCK`&:` M@0`P(`LB`$`J@9`$$2C@`#0HS`S2JM8HR)40,9H`$PNI@]HLX3S[(8`!4*`# M`Q@ABBY8@0X8.UD46!8%T_.4`@9PV.DR`"(P=@`,>0*HD%"`(.M"!!WHPPLA6 MMK*7)<(6>+0%!>S&!+&UP%#:&8=`KH,'86""""R``@L$!0$.H$)W'K.%$"R` MO"@X01DZ4`)W"L9`*SB!`Q(`K'74X0&;C0(X8M2!$ZCULUOP[S7"<`*B=H,[ M#P&"_QF"T`'R`5,[,%B!`+B#AA4$X;$[*AL`P!!4<)Y(90$)%](QB`"G.@0P$NH)$3\(5A?D`!1\H0@QD%@`4FT$@9 MG""8/O^Y`B@P0N0"((0K<)HC/VE#%#GY![_9Q`@+`(J45_\`7"A8(`L1N;01 M2*`$%!A@!2N```J0(`0,X``(&)3!`MX`@38D882G@D,,3L`&`Z`J`&>(``)& MX('%0N$'L=J1!)@PA06-[(` M(\3A!0\PG"**<`5!JW8<3&$!$DK`L*(C9`)(\``-DJ&`"^"!&72-L"'\P&82 MO('F84A!I#(`:8U<(`98?(&?(^T&-QS![&ZXP`Y`2&A#UP`,8#@"IW,0@0*@ M+%(Q@+2DJ^&J.`S!`I5\PQ1JT*;_$SC!#Z(F=05,30<[C&/E%:B"`0#@!QF\ M.M85F+4V5##V')3][&,(<2[+@*8%`"%(3#!@PLI3JK7&0+=%!A'D@- M"##8`P*^X()+A4$$8/A!#Z@I`5T:0`DB0,-A];:`*T2@"0#`U`L*,H,(?(`( M'+A#C'YP`>IQLP<0^`"AV.$')PR`#Q%0``>88HWP,+9@`#B2$Q3H$H`PD M2-(#1@"%#$A`;R[0`%```@&`3"*``"=@`@KP<7!P!ZQR'S4Q`A\0:4=@!#BP M!D1V:R:`!DEP`#@@!B50!%2E7\W$%4!$"#SG<_@!!*TA=`1@!S`(@Q,0*$FW M3'#0='C`_X(*LBW54G57QQ$G4`(!P`0?4$E?-P=0,G93(``Q$`,%$08D',[ M4F@60P1-F`<*(`(;<0($\"4,D'>1-@.5]BHPL`%M,@7\,`0-T`$S``8GD&") M5VH4T'B/QU5/("D2T`!;I7E)^#%,Z(1/2`#X(@<"\(-X$`,E0`$L<`8+T`8L M^%&"<``NH`7:5@"')0$P(`!6I0,@`#X( M\3I^D`$;<`8Z@``^`"E8!"5"05=0(HM6T`!4``-#@`0(0``,@&:2`%$/"#/%8%93!%49`%,I`$7(!Y&F$%3*!*K;1S M/6`&>\`9+]1#;$>%-7`&JO0"6/`%`Y`1-<`$KC('8+AW=<``Q9@1=-<2 M2',`#.`$9J``/A``<;AX<^AX?P!YD=8'3'!8+-!(?!@`8_W7C!O``AT`!4$``-U@#/='`GC4&FI!!!N0`0YP`2V@2$"0 M/EN0`4\!`F$@+TA8'7+@*2O0=6Z@`1H@`O;H2%-``CZ0!SK0`#`@`S>``!EH M,2"@3$ZY5`@_P(C@`'<51](91,@``9M@#3]DB20 M4*-C<0$ZX'5@QT2=!P908`50,*U"X`0MV3$O*2GR\85ZAP1$`Z%Z)_^A0-`# ML:88104A$$(73421HR:'=/B4&O$!+4!D=&<#*2IK*UH'8C<6T"JMTUH$/2`H M_VB/.0`&(C`$,(`#="!R@X`=97`%XX@D.W(,<$`#8J`!`3``:B<&,G``7`!7G`%IB8%7^INA`(#/[`!`F"K'1!^1(!8G+>! M#/``$+`!6)`==GH!@@8`,W`%"O`-95D&!,@5."`W0*``)O`!+,``&C`H"0H. M'7J67`!9=2'2^0`BU` M!N,G"-4``W\P,&5)7EF@`2]@.-KB!R\@`T:@!'B0'D"P`%QX'A1P`0,0`Y%R M`'@Y!X(%!&MP!!'PMRW0`"AS*10`!0+P01(P!)^*,O@2`,YH`P>0`%P0!!N0 MDO.'?W)@!UM!OQ52!A9P"=C074Z`!$1!:%)A+?F,0^\!`JP8QO1?^T`+R(!CN)`$L0#)TITHT$*&N(@/_2(%.$#S%YQRN ML2H?VI1U6`%'4``80`(<8043F'GYZ@=*Z,10_'$YAP5U,`%JT``M$`&55`,L MD`844@@SLP!(0$7S43NU`Q'P(@(;6S^U0B(,,`0?L`;GD;[K^R@L8`1QP4UX M.9'G0:8)8%*/4@P/(``A"0%/$`0S(!*<6WP)D,`R#`-A,`!($`:XQW`37,$( M(0<8C`D3`"P/T``ZD`-O8`"X`95_E@,B\%@@@*P5\`8HD`$WP%(M+`@O[/]; M)1$'#+E`&N!!7N:`.XP'G`$>1%-%04RLD>2 M,.1!R!E!!5H#'G`'$D"45$`$A_0&DX8R8,PJ,*"%U[P`)9`&8C".*H`%3D`! MZK7&NANO!?`"`#``5Y<8^*H-_!RO>_#/R/E!=+4$3I``..`#-@`"F)<#'M`I MQ`:Z*P`&>5`2+24=$48-6A4"4Q0J%4(@#\`$4,`"V.')!$"[$=4YI&P`]!L' M'+`"%Y`%+A#0?@HE6:`#F6$`*V8`,X`$`I`&.(`=SN@`-K&A0^`%7F`#$=T$ MP8BF)_,Z- M>Y\>,+2PQ$JJK<]SD(O\*00=,.53S@)HT+GX..49\`0C&6FSYI7<&H;5X%9` M(-V/9`$&@`1DP6AD:`!@#9<=)H*@(IS,.$W MTXGV&P$_T`(D<-<63,P>7@E"0B)`@`4]<`)OD`,Z,`9HD`4[T``&L`%N$.UO M@/^?Q($%6/`#OY8#2)`'*(,I?N"4=GN0O*,>0J=EA)`>#.!E#"`&`6"11-`# M3N`$6N`#6H"]A1`SI(T`'>L-3-3D1W@`MO9(5=#P#7\%0X`I$T"%U\P^& M%L"+=!$'CR;F$-%#<8VLS-PFTFX$KR/G?P M#8^G<9`"!6#$.5`%-5`#)8T$1J`!16XD20#>U1<$0[`%7-`#)3`$'K`7QJ`! M!$`"5B`"+$``7,`%1F`&`[`!0G`#WZ!*^=T4+/(H>"DT')`"W$P:-]"!1@@`+,W`!"0`5N`BAB0S]<\!0.PH@WS&`2,'!!S``3S@9A70!PC0@7(G``0,<$N08["&`!(@06R;,8:``A%.8,DFL*#%'0H`\'J+&_*&@!`P.4886"!B!H(.!":83.$D`TP!:,J%]0MBA18Q&@I. M(&I4P0VK*9H^U!S1H M$$<7#0P`,K.7'A2EDN(0]]]`@`0^V!5".>=W( M$$!#&M!@$Q`&VB*#50$DP)9!#(AV0"4\P,'`C@Q,P,.%0);3XDE`7CCB!!+T MZ`N0,KCEAT(!%,DB$`\`X$0/0*`VP8[=E&?.A6+)H9!Y'(B1PA([)K"$"B^, M%L>6//I89%LB&O1F'`\XX80:MB79D6F11#F)'TDT"8`6`#S_,$M'=QS`XD$) M))"G$TL$($=;%W8TP7DB6G3/DQ2.V4V4'$8R0:2=AO7IDRXPP(,,"7C84:$& MJ1DG#&UYY(=!!N&`@QUQ MM&7>@)/<(;#`<:"&;QP#"XPN>WYP&Q8V0!SP`I`3Q/'.'W6@6TX=Y7@$!`\_ M^E''"S?Z`LE8!ZA0!P]6^1$`!QD>\.*`(+)8L!\)W^&>'PS,,0?"$:N@PHLT M].OI/0->7`=#$MPAPP$<1]PQA4EB_^$6$.R(Z-$?%R)I$)B?)ODUSQJXX",^ M$T8,3 M!(2AP`4UY"`1`D[`D`"O@=?[I!QV<'0-$*I&4D=;,DR"FB]P!+#+"V*VQHD*#=I>"1.AD\X%7X\!=V3':/G\E@8O?I M"+I&]Z,D(/^/>6$B!1"2Y+K`T>=)/H.#$5H@.4/4H`M$F,$`+G"$-TQA`U:P M0BA@X$'BF%!S<+##4L#4ME5=2`YT(`ZWLC,:]\P"'U%#5\-H-S\)T.!V&?L8 MMV`G%,_1X4W$(8Y!)A`UY(5Q2SGAP/QNYSV0=6,..*B*Q2YD#Y`11S$#DD`< MK0*R:V!C..@#7Y":U\'1C>V+9ZQ8\OR`P4UQJRV/`%(^Y#`@>$QC?YF*0]X. M(@?:16QI21DCBJ'R]@% MAW?(($QVR%+!@&!"$[*`A8=()B).H``6&`$`\2NF-*=)S6I:\YJ?V,RF-K?) MS6YZ\Q[X`8$)H/`!-R#!#5!`P0P:H``S5&IKWXRG/.=)SWK:\Y[XQ.8=)."# M(1C'`T*`@`&BH`@]T84>&,"@!`[(PPZ^("`# M[0AV$@VI2$=*TI)&M$@APQWTEC2-5)KTI3"-J4QG2M.:VO2F.,VI3G?*TY[Z 4]*=`#:I0ATK4HAKUJ$B-1"```#L_ ` end